Latest News on COR

Financial News Based On Company


Advertisement
Advertisement

Cencora Inc (COR) PT Raised to $415 at Barclays

https://www.streetinsider.com/news.php?id=27365753&classic=1
Barclays analyst Glen Santangelo has raised the price target for Cencora Inc (COR) to $415. The full details of this analyst action are available only to premium subscribers.

Weekly Recap: FTC sues to block MWI sale and analysts raise price targets

https://www.tradingview.com/news/tradingview:ebf916162c582:0-weekly-recap-ftc-sues-to-block-mwi-sale-and-analysts-raise-price-targets/
The FTC and attorneys general from 13 states are suing to block Cencora's planned $3.5 billion sale of MWI Animal Health to Covetrus due to competition concerns, a deal Covetrus intends to defend. Despite the legal challenge, JPMorgan and TD Cowen have both raised their price targets for Cencora.

Two Medical Giants Diverge in Strategy as Investors Face a Choice Between Steady Returns and High Growth

https://nai500.com/blog/2026/11/two-medical-giants-diverge-in-strategy-as-investors-face-a-choice-between-steady-returns-and-high-growth/
Amgen (AMGN) and Vertex Pharmaceuticals (VRTX) offer investors distinct choices: Amgen provides steady returns with a lower valuation, strong cash flow, and diversified operations, appealing to those seeking stability. Vertex, while growing faster with conservative finances and a promising pipeline, comes with a higher valuation and concentrated revenue. Investors must weigh these differences based on their individual risk and return preferences.

Granted at no cost, Pawan Verma's 4,231 Cencora (COR) stock units vest from 2027 through 2029.

https://www.stocktitan.net/sec-filings/COR/form-4-cencora-inc-insider-trading-activity-d122b25215e3.html
Cencora (COR) Executive Vice President, Chief Data & Info Officer Pawan Verma was granted 4,231 restricted stock units on November 11, 2026, for no consideration. These units will vest in three equal annual installments on November 11, 2027, 2028, and 2029. Following this transaction, Verma's reported post-transaction balance of restricted stock units is 4,231.

Form 4 Cencora Inc: Elizabeth S. Campbell (Executive Vice President) For: 11 November

https://ng.investing.com/news/stock-market-news/form-4-cencora-inc-elizabeth-s-campbell-executive-vice-president-for-11-november-93CH-2807491
This article reports on a Form 4 filing for Cencora Inc, indicating an insider transaction by Elizabeth S. Campbell, Executive Vice President, on November 11. It's a brief announcement providing details about the executive and the date of the reported activity.
Advertisement

Form 4 Cencora Inc: Eva C. Boratto (CFO) For: 11 November

https://uk.investing.com/news/stock-market-news/form-4-cencora-inc-eva-c-boratto-cfo-for-11-november-93CH-4982189
This article reports on a Form 4 filing for Cencora Inc., specifically detailing activity by Eva C. Boratto, the company's CFO, on November 11. The brief piece indicates Cencora's stock (COR) saw a 2.76% increase.

Granted at no cost, 4,402 Cencora (COR) stock units vest in three equal annual installments.

https://www.stocktitan.net/sec-filings/COR/form-4-cencora-inc-insider-trading-activity-3fdace31499c.html
Elizabeth S. Campbell, Executive Vice President of Cencora, acquired 4,402 restricted stock units on November 11, 2026. These units were granted without cost and are set to vest in three equal annual installments on November 11, 2027, 2028, and 2029. This transaction was reported in an SEC Form 4 filing.

Cencora (COR) grants Lazarus Krikorian stock units vesting in three equal annual installments.

https://www.stocktitan.net/sec-filings/COR/form-4-cencora-inc-insider-trading-activity-ceae8c9b1c23.html
Cencora, Inc. (COR) has granted its SVP & Chief Accounting Officer, Lazarus Krikorian, 3,216 restricted stock units. These units were acquired on November 11, 2026, for no consideration and will vest in three equal annual installments on November 11, 2027, 2028, and 2029. Following this transaction, Krikorian's reported post-transaction position is 3,216 restricted stock units.

A 4,682-unit stock grant for Cencora (COR) CEO Mauch vests in three installments through 2028.

https://www.stocktitan.net/sec-filings/COR/form-4-cencora-inc-insider-trading-activity-4e58cce1ce18.html
Cencora (COR) President & CEO Robert P. Mauch acquired 35,589 common shares after performance criteria were met and received a no-consideration grant of 4,682 restricted stock units (RSUs). These RSUs will vest in three equal installments on November 12, 2026, 2027, and 2028. Mauch also reported withholding shares for tax obligations related to both performance share units and restricted stock units.

FTC plans to sue to block Covetrus's $3.5 billion merger with Cencora's MWI Animal Health, Semafor reports

https://mlq.ai/news/ftc-plans-to-sue-to-block-covetruss-35-billion-merger-with-cencoras-mwi-animal-health-semafor-reports/
The Federal Trade Commission (FTC) is reportedly planning to sue to block the $3.5 billion merger between Covetrus and Cencora's MWI Animal Health unit. The FTC intends to argue that the deal would increase costs for pet owners and veterinary clinics and lead to a highly concentrated market, as both companies are major national suppliers of veterinary medical supplies. Cencora stands to receive $1.25 billion in cash and equity in Covetrus's parent company, totaling about 34.3% of the combined entity.
Advertisement

We Like Cardinal Health's (NYSE:CAH) Earnings For More Than Just Statutory Profit

https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/we-like-cardinal-healths-nysecah-earnings-for-more-than-just
Cardinal Health (NYSE:CAH) recently reported strong earnings, which was well-received by the market. Analysis of the accrual ratio revealed a negative value of -2.58 for the year to September 2026, indicating that the company's free cash flow significantly exceeded its reported profit. Additionally, unusual items reduced profit by US$840m, suggesting that without these non-recurring charges, future profits could be higher, leading to an optimistic outlook on Cardinal Health's earnings potential.

Vesting taxes account for 1,673 shares withheld from Cencora (COR) CEO Mauch.

https://www.stocktitan.net/sec-filings/COR/form-4-cencora-inc-insider-trading-activity-058e115584ab.html
Cencora, Inc. (COR) CEO Robert P. Mauch converted 4,066 restricted stock units into common stock on November 6, 2026. As part of this transaction, 1,673 shares were withheld at a price of $333.56 per share to cover tax withholding obligations related to the vesting of these units. These restricted stock units were granted without consideration and are set to vest in three equal installments.

Form 4 Cencora Inc: Elizabeth S. Campbell (Executive Vice President) For: 6 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-cencora-inc-elizabeth-s-campbell-executive-vice-president-for-6-november-93CH-5696555
This article reports on a Form 4 filing for Cencora Inc., detailing an insider transaction by Elizabeth S. Campbell, Executive Vice President, on November 6th. The filing indicates a change in her beneficial ownership of the company's stock.

Form 4 Cencora, Inc. For: Nov 06 Filed by: Campbell Elizabeth S

https://www.streetinsider.com/SEC+Filings/Form+4+Cencora%2C+Inc.+For%3A+Nov+06+Filed+by%3A+Campbell+Elizabeth+S/27322972.html
This SEC Form 4 filing reports changes in beneficial ownership of Cencora, Inc. (COR) stock by Executive Vice President Elizabeth S. Campbell. On November 6, 2026, Campbell acquired 1,830 shares of common stock through the vesting of restricted stock units and disposed of 846 shares to satisfy tax withholding obligations, resulting in a net beneficial ownership of 20,439.085 shares. The filing details the derivative securities transactions and the vesting schedule of the restricted stock units.

Cencora, Inc. (COR) stock price, news, quote and history

https://au.finance.yahoo.com/quote/COR/
This Yahoo Finance page provides a comprehensive overview of Cencora, Inc. (COR) stock, including its current price, market performance, and key financial statistics. It features a real-time stock quote, interactive chart, and links to recent news and videos discussing related market trends and CEO insights from other companies. The page also offers detailed valuation measures, profitability metrics, and balance sheet information for Cencora.
Advertisement

Cencora stock enters fiscal 2027 with specialty-led growth outlook

https://www.ad-hoc-news.de/boerse/news/corporate-news/cencora-stock-enters-fiscal-2027-with-specialty-led-growth-outlook/70485952
Cencora reported stronger fiscal fourth-quarter results, with revenue up 5.5% and adjusted diluted earnings per share increasing 21.4%. The company expects fiscal 2027 adjusted diluted earnings per share to grow by 8% to 10%, driven primarily by its Specialty Pharmaceutical and Provider Services segment. Cencora also raised its quarterly dividend by 10% and plans additional share repurchases.

Cencora (NYSE:COR) Could Be A Buy For Its Upcoming Dividend

https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/cencora-nysecor-could-be-a-buy-for-its-upcoming-dividend-2
Cencora (NYSE:COR) is set to trade ex-dividend soon, with a payment of US$0.66 per share, resulting in a trailing yield of 0.8%. The company demonstrates strong dividend sustainability, with a low payout ratio of 13% from income after tax and 12% from free cash flow, indicating good coverage. Cencora has also shown rapid earnings per share growth of 20% annually over the last five years, suggesting it reinvests heavily for future growth and can potentially increase dividends further.

DataMEDS Completes First Compounded Peptide Sale

https://grafa.com/en/news/united-states/datameds-ai-corexa-pharmacy-first-compounded-peptide-sale
DataMEDS AI announced that its Corexa Pharmacy subsidiary has completed its first commercial sale of a compounded peptide, operating under the HHS Enforcement Discretion Policy. The sale involved one of six peptides identified by the FDA's Pharmacy Compounding Advisory Committee, though these compounded drugs are not FDA-approved. The company is developing its pricing model and intends to market these offerings to prescribing physicians.

Cencora, Inc. (COR) latest stock news and headlines

https://au.finance.yahoo.com/quote/COR/news/
This article provides a compilation of recent news and headlines concerning Cencora, Inc. (COR), including its latest stock performance, dividend announcements, and Q3 and Q4 CY2026 earnings reports. Several analyst takes and earnings beat analyses are featured, indicating strong financial results for the company. The page also includes performance overview data comparing COR's trailing total returns against the S&P 500.

Cardinal Health (CAH) Lifts Guidance As Investors Ask If The Story Is Fully Valued

https://simplywall.st/stocks/us/healthcare/nyse-cah/cardinal-health/news/cardinal-health-cah-lifts-guidance-as-investors-ask-if-the-s
Cardinal Health (CAH) reported a stronger-than-expected first quarter with increased revenue and earnings, leading to raised fiscal 2027 profit guidance. The company's stock has seen significant gains, though its current valuation is considered fair based on long-term earnings forecasts. However, its high P/E ratio compared to peers suggests investors are already paying a premium for the growth story, prompting questions about future upside potential.
Advertisement

Cencora stock enters fiscal 2027 with stronger earnings outlook

https://www.ad-hoc-news.de/boerse/news/corporate-news/cencora-stock-enters-fiscal-2027-with-stronger-earnings-outlook/70473648
Cencora Inc. reported stronger fiscal fourth-quarter results and provided a raised earnings outlook for fiscal 2027, driven by expected growth in its specialty segment. The company also announced a 10 percent increase in its quarterly dividend, signaling continued shareholder returns. Additionally, Cencora is restructuring its reporting to separate Pharmaceutical Distribution and Services from Specialty Pharmaceutical and Provider Services, to highlight the faster-growing specialty activities.

Cencora, Inc. (COR) Seasonal returns chart

https://au.finance.yahoo.com/quote/COR/seasonality/
This article provides a seasonal returns chart for Cencora, Inc. (COR), showing the average monthly price return from 2016 to 2026. It highlights the company's current stock price and recent performance, along with links to financial data and analysis. The page also mentions the replay of Cencora's Q4 2026 earnings call for further insights.

Cencora, Inc. (COR) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/COR/seasonality/
This Yahoo Finance article provides a seasonal returns chart for Cencora, Inc. (COR), displaying the average monthly price return from 2016 to 2026. The page also shows current stock performance, market data, and links to research and financial information for Cencora.

Here’s How Much You Would Have Made Owning Cencora Stock In The Last 10 Years

https://www.benzinga.com/news/26/11/63010348/here-s-how-much-you-would-have-made-owning-cencora-stock-last-10-years
Cencora (NYSE: COR) has significantly outperformed the market over the past decade, achieving an average annual return of 20.98%. An initial investment of $1000 in COR stock 10 years ago would now be worth $6,698.79, demonstrating the substantial impact of compounded returns. The company currently holds a market capitalization of $64.82 billion.

Cencora Inc. stock underperforms Friday when compared to competitors

https://www.marketwatch.com/data-news/cencora-inc-stock-underperforms-friday-when-compared-to-competitors-34aa4c2e-2c590901c649
Shares of Cencora Inc. (COR) fell 1.80% on Friday, underperforming the broader stock market which saw the S&P 500 Index rise while the Dow Jones Industrial Average declined. This marks the second consecutive day of losses for the stock.
Advertisement

Cencora fiscal Q4 revenue rises 5.5% to $88.4 billion, adjusted EPS up 21% to $4.66; fiscal 2027 guide $19.40-$19.75

https://mlq.ai/news/cencora-fiscal-q4-revenue-rises-55-to-884-billion-adjusted-eps-up-21-to-466-fiscal-2027-guide-1940-1975/
Cencora reported a 5.5% increase in fiscal Q4 2026 revenue to $88.4 billion, with adjusted diluted EPS up 21.4% to $4.66. The company also provided fiscal 2027 guidance, projecting adjusted EPS of $19.40-$19.75, along with revenue growth of 3% to 5% and adjusted operating income growth of 4% to 6%. Additionally, Cencora announced a 10% increase in its quarterly dividend to $0.66 per share.

3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility

https://www.tradingview.com/news/zacks:35e4d1ef5094b:0-3-stocks-in-focus-that-hiked-dividends-amid-ongoing-market-volatility/
Amid persistent market volatility driven by inflation concerns and fears of an AI slowdown, this article highlights three dividend-paying stocks that could offer stability and income. Becton, Dickinson and Company (BDX), Cencora, Inc. (COR), and UniFirst Corporation (UNF) are featured, each having recently announced dividend hikes and demonstrating a history of consistent dividend growth. The piece also touches on recent market crashes and the Federal Reserve's actions to combat inflation.

Cardinal Health Lifts Outlook as Specialty Drug Unit Beats, Shares Hit Record

https://finance.biggo.com/news/4b2ac4e9-a17c-4c6f-a838-781e0a10c489
Cardinal Health raised its fiscal 2027 adjusted EPS guidance after reporting stronger-than-expected first-quarter revenue and EPS, driven by its Pharmaceutical and Specialty Solutions unit. The specialty business, particularly in urology and oncology, saw high-teens growth, while other segments lagged. The company also repurchased $500 million in stock and renewed key contracts, including one with CVS Health extending beyond its 2028 split.

Cencora Inc. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/cencora-inc-stock-underperforms-thursday-when-compared-to-competitors-ada31d94-b9b7353aa05d
Cencora Inc. (COR) shares dropped 4.05% on Thursday, closing at $339.68, during an overall weak trading session where the S&P 500 Index and Dow Jones Industrial Average also experienced significant declines. This decline ended a five-day winning streak for the stock.

Key facts: Cencora FY26 growth; OneOncology margins; Leerink target up

https://www.tradingview.com/news/tradingview:c906582b83dd7:0-key-facts-cencora-fy26-growth-oneoncology-margins-leerink-target-up/
Cencora reported a 5% revenue increase to $337.4 billion and a 12.3% rise in adjusted EPS to $17.97 for fiscal 2026, while forecasting fiscal 2027 EPS of $19.40–$19.75. The company also raised its dividend by 10%. The OneOncology acquisition in February 2026 improved gross profit margins, though this was partially offset by increased sales of lower-margin GLP-1 products. Leerink Partners subsequently raised its price target for Cencora to $405 from $388.
Advertisement

Cardinal Kicks Off 2027 With Margin Expansion and Accelerating Specialty Business

https://www.morningstar.com/company-reports/1508500-cardinal-kicks-off-2027-with-margin-expansion-and-accelerating-specialty-business
Cardinal Health (CAH) has started its 2027 fiscal year strongly, driven by margin expansion and growth in its specialty business. Analyst Keonhee Kim of Morningstar has raised the company's valuation due to these positive developments. Cardinal Health is a major player in pharmaceutical wholesale and distribution, holding approximately one-fourth of the U.S. market share.

DarioHealth stock gets new chairman ahead of earnings call

https://www.ad-hoc-news.de/boerse/news/nebenwerte/dariohealth-stock-gets-new-chairman-ahead-of-earnings-call/70460092
DarioHealth has appointed John R. Palumbo as its new chairman, effective November 3, 2026, succeeding Yoav Shaked. Palumbo, with over four decades of healthcare experience, will join the upcoming third-quarter 2026 earnings call on November 12 to discuss the company's strategy in converging consumer and payer-funded healthcare. DarioHealth aims to position its AI-powered platform for chronic condition management across health plans, systems, and employers.

Cencora FY27 EPS guidance misses estimate at $19.40-$19.75

https://scanx.trade/stock-market-news/companies/cencora-fy27-eps-guidance-misses-estimate-19-40-19-75/55341630
Cencora Inc. has issued fiscal year 2027 guidance for adjusted earnings per share (EPS) between $19.40 and $19.75, falling below the consensus analyst estimate of $19.70. The company also projected total sales for FY2027 in the range of $347.519 billion to $354.267 billion, with the upper bound exceeding analyst estimates but the lower bound significantly below. This suggests potential margin compression or higher operating costs, impacting top-line expectations.

Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand

https://www.tradingview.com/news/zacks:528d3a055094b:0-cencora-q4-earnings-revenues-beat-on-specialty-growth-margins-expand/
Cencora (COR) reported strong fourth-quarter fiscal 2026 results, surpassing earnings and revenue estimates driven by higher specialty pharmaceutical volumes, GLP-1 drug demand, and the OneOncology acquisition. The company announced a new specialty-focused organizational structure, an agreement to acquire American Oncology Network, and a 10% dividend increase, reinforcing its long-term growth strategy despite pressures from lower-margin GLP-1 products and acquisition-related expenses. Cencora also issued an upbeat fiscal 2027 outlook, projecting continued growth in earnings and revenues.

DarioHealth Appoints John R. Palumbo Chairman of the Board

https://www.citybiz.co/article/929232/dariohealth-appoints-john-r-palumbo-chairman-of-the-board/
DarioHealth Corp. (Nasdaq: DRIO) has appointed John R. Palumbo as Chairman of its Board of Directors, effective November 3, 2026. Palumbo, who joined the board in April 2026, succeeds Yoav Shaked and brings over 40 years of healthcare leadership experience. This leadership change aims to bolster DarioHealth's strategy of integrating consumer engagement, AI-driven clinical insights, and provider-supported care for chronic condition management.
Advertisement

Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care

https://www.prnewswire.com/news-releases/dario-names-veteran-healthcare-executive-john-r-palumbo-chairman-of-the-board-as-company-positions-itself-to-lead-the-convergence-of-consumer-and-payer-funded-care-302928176.html
DarioHealth Corp. has appointed John R. Palumbo as Chairman of its Board of Directors, effective November 3, 2026. This appointment comes as the company focuses on the convergence of consumer health and payer-funded chronic care management, a market shift DarioHealth believes it is well-positioned to lead with its AI-powered platform. Mr. Palumbo, a veteran healthcare executive, will share the Board's perspective on these market shifts during Dario's third quarter 2026 earnings call on November 12, 2026.

Stock replaces a $35,000 cash retainer for Cencora (COR) director Dennis M. Nally.

https://www.stocktitan.net/sec-filings/COR/form-4-cencora-inc-insider-trading-activity-e9b7a441f39a.html
Cencora director Dennis M. Nally acquired 106 shares of common stock on October 30, 2026, in lieu of a $35,000 quarterly cash retainer. The shares were valued at $330.84 each, bringing his direct holding to 13,294 shares. This transaction was reported in an SEC Form 4 filing.

Form 8K Cencora Inc For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-cencora-inc-for-4-november-93CH-4929025
This article reports on the filing of a Form 8K by Cencora Inc on November 4, 2026. The brief announcement from Investing.com indicates that the document is now publicly available. No further details about the content of the Form 8K are provided within the article itself.

Cencora (COR) director Ellen Cooper receives 91 stock units instead of a $30,000 cash retainer.

https://www.stocktitan.net/sec-filings/COR/form-4-cencora-inc-insider-trading-activity-b815b2dc72ca.html
Cencora, Inc. director Ellen Cooper was granted 91 restricted stock units on October 30, 2026, as a substitute for her $30,000 quarterly cash retainer. The receipt of these shares is deferred until her cessation of service. Following this transaction, her direct post-transaction position in common stock stands at 984 shares.

Cencora: Fiscal Q4 Earnings Snapshot

https://ca.finance.yahoo.com/news/cencora-fiscal-q4-earnings-snapshot-115104691.html
Cencora, Inc. (COR) reported strong fiscal fourth-quarter earnings, with net income of $519.4 million, or $2.71 per share, and adjusted earnings of $4.66 per share, surpassing Wall Street estimates. The prescription drug distributor also exceeded revenue forecasts, posting $88.35 billion for the quarter. For the full year, Cencora reported a profit of $3.48 billion on revenue of $337.4 billion and provided a positive earnings outlook for the next fiscal year.
Advertisement

Cencora Realigns Corporate and Reporting Structure

https://www.tradingkey.com/news/stocks/262273811-
Cencora, Inc. (NYSE: COR) has announced a realignment of its corporate and reporting structure to enhance execution and transparency. This reorganization establishes two main operating segments: the Specialty Pharmaceutical and Provider Services segment, led by Richard Tremonte and comprising all specialty businesses, and the Pharmaceutical Distribution and Services segment, which includes remaining U.S. operations and its European wholesale pharmaceutical distribution business.

Form 8-K Cencora, Inc. For: Nov 04

https://www.streetinsider.com/SEC+Filings/Form+8-K+Cencora%2C+Inc.+For%3A+Nov+04/27285342.html
Cencora, Inc. filed a Form 8-K announcing its earnings for the fiscal quarter and year ended September 30, 2026. The company issued a news release and is conducting a conference call and webcast on November 4, 2026, at 8:30 a.m. Eastern time to discuss these results. The Form 8-K also details the company's registered securities and filing obligations.

Cencora reorganizes into two reporting segments

https://www.streetinsider.com/Corporate+News/Cencora+reorganizes+into+two+reporting+segments/27285335.html
Cencora, Inc. has announced a corporate and reporting structure realignment, consolidating its businesses into two new segments: Specialty Pharmaceutical and Provider Services, and Pharmaceutical Distribution and Services. This reorganization aims to provide shareholders with a clearer view of the company's strategic progress and its efforts to create sustainable, long-term value. The company has filed recast unaudited summary segment financial information for fiscal years 2025 and 2026 with the SEC.

Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus

https://sg.finance.yahoo.com/news/cencora-announces-organizational-reporting-structure-113500520.html
Cencora, Inc. has announced a new organizational and reporting structure aimed at strengthening execution, enhancing visibility, and further advancing its leadership in specialty pharmaceutical solutions. The realignment consolidates specialty businesses under one leader, Richard Tremonte, forming the Specialty Pharmaceutical and Provider Services segment. Remaining U.S. businesses and a European wholesale distribution business will be organized under the Pharmaceutical Distribution and Services segment, with specific verticals for Health Systems and Retail Pharmacy and Alternate Care.

Form 4 Cencora Inc: Pawan Verma (EVP, Chief Data & Info Officer) For: 30 October

https://ca.investing.com/news/stock-market-news/form-4-cencora-inc-pawan-verma-evp-chief-data--info-officer-for-30-october-93CH-4930246
This article reports on a Form 4 filing for Cencora Inc., detailing an insider transaction by Pawan Verma, the EVP, Chief Data & Information Officer, on October 30. The content is concise, indicating only the occurrence of this filing without further specific details of the transaction.
Advertisement

Cencora (COR) Q4 2026 Earnings Call Transcript

https://fortune.com/company/amerisourcebergen/earnings/q4-2026/
This document provides the full transcript of Cencora's Q4 2026 earnings call, which took place on November 4, 2026, at 8:30 AM EST. The call featured company participants including Bennett Murphy, Bob Mauch, and Eva Boratto, as well as several analysts from various financial institutions.

Chronic conditions account for roughly 90% of U.S. health spending. DarioHealth appoints a new chairman.

https://www.stocktitan.net/news/DRIO/dario-names-veteran-healthcare-executive-john-r-palumbo-chairman-of-5dr90smimesr.html
DarioHealth (NASDAQ: DRIO) has appointed John R. Palumbo as Chairman of its Board, effective November 3, 2026. This appointment positions the company to address the convergence of consumer-directed healthcare and payer-funded chronic care management, a market shift where chronic conditions account for approximately 90% of U.S. health spending. Palumbo will join the company's third-quarter earnings call on November 12, 2026, to discuss strategic priorities in this evolving landscape.

Form 4 Cencora Inc: Dennis M. Nally (Director) For: 30 October

https://ca.investing.com/news/stock-market-news/form-4-cencora-inc-dennis-m-nally-director-for-30-october-93CH-4926980
This article reports on a Form 4 filing for Cencora Inc., indicating that director Dennis M. Nally made a transaction on October 30. The brief report from Investing.com provides a direct notification of this insider activity, which is a standard disclosure for public companies.

Form 4 Cencora Inc: Dennis M. Nally (Director) For: 30 October

https://ng.investing.com/news/stock-market-news/form-4-cencora-inc-dennis-m-nally-director-for-30-october-93CH-2779543
This article reports on a Form 4 filing for Cencora Inc, indicating a transaction by Director Dennis M. Nally on October 30th. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. The article provides the title of the filing and mentions Cencora Inc's stock symbol (COR).

Form 4 Cencora Inc: Lauren M. Tyler (Director) For: 30 October

https://ca.investing.com/news/stock-market-news/form-4-cencora-inc-lauren-m-tyler-director-for-30-october-93CH-4926945
This article reports on a Form 4 filing for Cencora Inc, indicating that director Lauren M. Tyler executed a transaction on October 30. The brief notice from Investing.com provides no further details regarding the nature or value of the transaction.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement